Two New Canada Research Chairs in the Department of Pharmacology & Toxicology
The Department is very proud to announce that two of our colleagues have been awarded prestigious Canada Research Chairs.
Dr. Rachel Tyndale, is a Professor in the Departments of Pharmacology & Toxicology and Psychiatry. She has been awarded a Tier 1 Canada Research Chair in Pharmacogenomics. Dr. Rachel Tyndale is a Senior Scientist and Head of the Pharmacogenetics Lab in the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health. Dr Tyndale is an expert in the investigation of genes that can alter drug metabolism and create interindividual differences in drug efficacy, toxicity and drug dependence.
Dr. Ana Andreazza, is an Associate Professor in the Departments of Pharmacology & Toxicology and Psychiatry, and an Independent Scientist at the Centre for Addiction and Mental Health. Dr Tyndale is an expert in the investigation of genes that can alter drug metabolism and create interindividual differences in drug. She has been awarded a Tier 2 Canada Research Chair in the Molecular Pharmacology of Mood Disorders. Dr Andreazza’s research focuses on the understanding of the role of redox modulations and mitochondrial dysfunction in mental illness, especially in mood disorders.
The Canada Research Chairs are an investment of approximately $265 million per year in Canadian research. The chairholders are chosen from among the country’s most accomplished and promising scientists, working across research disciplines including engineering and the natural sciences, health sciences, humanities, and social sciences. The Department of Pharmacology & Toxicology is delighted to congratulate these two excellent scientists."
The awards add to an impressive list of Chairs held by our faculty members, including Drs. Jeffrey Meyer, Subodh Verma, Peter Roy, Jack Uetretch, and most recently, Leonardo Salmena. Dr. Salmena was awarded a Tier 2 Canada Research Chair in Signal Transduction and Gene Regulation in Cancer in 2014. As a pharmacologist, Salmena and his team aim to better understand the molecular basis of acute myeloid leukemia in order to develop more effective therapies to conquer it.